News from Tuesday, February 3, 2026
Articles
ACHP Announces New Funding to Elevate Patient Voices in Diabetes Research
(2/2, Logan Lutton, Managed Healthcare Executive) reports “...The award is funded through the Eugene Washington Patient-Centered Outcomes Research Institute (PCORI) Engagement Award Program and is part of a broader PCORI initiative to support research focused on chronic disease. The effort will initially concentrate on diabetes, a condition that affects approximately 40 million people in the United States, according to the Centers for Disease Control and Prevention. An additional 115.2 million people ages 18 and older are estimated to have prediabetes.” Full
Prior Authorization Ranked Top Barrier to Health Care Access After Cost
(2/2, Giuliana Grossi, The American Journal of Managed Care) reports “...About 7 in 10 insured adults (69%) describe prior authorization requirements as either a major or minor burden when getting health care, according to the poll results. Roughly 1 in 3 (34%) identify prior authorizations as the single biggest noncost barrier they face—outpacing other common challenges such as understanding medical bills (17%), finding in-network providers (15%), and securing timely appointments (19%).” Full
Trump Is Right to Call Out Health Insurance Companies
(2/3, Kathy Oubre, RealClearHealth) comments “...Insurers and their pharmacy benefit managers (PBMs) have built a system that works against the very people it is supposed to serve by putting profits over patients. Prior authorizations that were once rare are now routine. Formularies shift constantly. Across cancer care, insurers increasingly impose step therapy, forcing patients to try and demonstrate intolerance to older and often inferior treatments before approving the therapy their physician originally selected.” Full
Press Releases
Research Spotlight: Use of Glucose-Lowering SGLT2i Drugs May Help Patients with Gout and Diabetes Take Fewer Medications
(2/2, Mass General Brigham Press Release) “...Compared to DPP-4i, SGLT2i use was associated with a 38% lower probability of starting allopurinol, a common urate-lowering drug. Patients using SGLT2i had fewer prescriptions for NSAIDs, colchicine and high-dose glucocorticoids, and had fewer gout flares. They also had fewer prescriptions for diuretic medications, especially loop diuretics. These findings were consistent in different sensitivity analyses, including when comparing SGLT2i to GLP1-RA, and in a repeat analysis in an external dataset.” Full
Journals
Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies
Natalie McCormick, et al.
January 30, 2026, Diabetes Care
Comparative Effectiveness and Persistence of Ixekizumab and Other b/tsDMARDs in Patients with PsA from a Real-World Setting: 12-Month Results from the PRO-SPIRIT Study
Helena Marzo-Ortega, et al.
February 2, 2026, RMD Open
Estimating Heterogeneous Treatment Effects with Real-World Health Data – A Scoping Review of Machine Learning Methods
Michael Möller, M.Sc, et al.
February 3, 2026, Value in Health
Reports
The Tufts-CEVR HEOR Leaders Survey: Perspectives on Organizational Support and Evidence Opportunities
February 3, 2026
KFF Health Tracking Poll: Prior Authorizations Rank as Public’s Biggest Burden When Getting Health Care
February 2, 2026